The Evivo Advocate Program
Together, we can make a meaningful difference in the lives of many.
Let's transform infant health, together.
Become an Evivo Advocate today
You’re already a trusted partner to families. Now join us in elevating the standard of care by offering Evivo for patient purchase.
Ensuring your success is our top priority
To help establish Evivo in your business, we offer tools to help you get started:
- On-site training
- Direct line of contact for product and support inquiries
- Patient education resources
- Marketing welcome kit
Join the advocate program today
As a trusted healthcare provider, you have the power to positively impact the health of your patients. By recommending and selling Evivo infant probiotic, you can play a crucial role in supporting patient health and well-being. We value your partnership and are committed to providing the highest quality products and support to help you achieve your patients’ health goals. Thank you for considering Evivo as part of your patient care strategy.
Get Evivo for your patients today
Evivo PowderShop this product
A daily powder intended for babies fed any amount of breast milk to help establish a protective gut microbiome and support healthy immune function.
Clinically shown to:
- Promote the growth of beneficial B. infantis EVC001 to establish a healthy gut microbiome
- Protect from potentially harmful bacteria linked to colic, diaper rash, eczema, allergies, and type 1 diabetes
- Significantly reduce gut inflammation
- Convert breast milk HMOs into metabolites that help guide healthy immune function.
Clean Label Project certified. Safe & well tolerated by infants.
How does Evivo work with breast milk to protect babies from within?
See our documented mechanism of action.
B. infantis EVC001 uniquely captures Human Milk Oligosaccharides (HMOs) found in breast milk, helping infants maximize nutrition from breast milk.
B. infantis EVC001 then consumes HMOs to colonize, or to replicate, establish, and persist, in the gut and help protect baby from potentially harmful bacteria. These harmful bacteria have been linked to colic, digestive discomfort, eczema, allergies, and type 1 diabetes.
Finally, B. infantis EVC001 converts HMOs into metabolites, key signaling molecules that help guide healthy immune system function. An overactive immune system has been associated with the development of allergies and other autoimmune conditions later in life.
Evivo is Clean Label Project Certified
Clean Label Project is a national nonprofit committed to transparency in food and consumer product labeling. The organization runs lab tests on hundreds of products and awards those that surpass FDA regulations. Evivo powder passed the testing and received certifications for Clean Label Project.
Best-in-Class Product Standards
Evivo products are designated as a Food for Special Dietary Use (CFR21 part 105) and are Generally Recognized as Safe, or GRAS for infant use. We maintain best-in-class standards for product testing, manufacturing, packaging, and distribution:
- Third-party testing ensures CFU (colony forming units) count and purity
- Each manufacturing batch includes a Certificate of Conformance
- All packaging is BPA free and protects Evivo from moisture, light, and oxygen
Since each baby is unique, you can choose the best way to feed Evivo.
Pour 1 sachet of Evivo powder into a small bowl or bottle.
Add breast milk or formula based on table. Mix well.
|Feeding method||Amount of breast milk or formula per sachet|
|Spoon, oral syringe, or medicine dispenser pacifier||1 tsp (approx. 5 mL)|
|Directly from finger, nipple, or pacifier||5-10 drops (for paste)|
|Bottle||Single feeding amount or 2 oz|
Use immediately once mixed. Discard leftovers. Do not store for later use.
- Give Evivo at the start of a feeding, so baby is likely to swallow more of it.
- It’s ok if baby doesn’t finish everything during a single feeding, still discard the rest.
- For best results, mix with room temperature or warm breast milk or formula. Some sediment is expected.
- Hold or sit baby semi-upright, supporting the upper back and neck – just as if feeding a bottle. Don’t tip head back – this can make it harder to swallow.
We know how Evivo works and can support our claims with scientific evidence – that sets us apart from others.
Effects of probiotic and symbiotic supplementation on ponderal and linear growth in severely malnourished young infants in a randomized clinical trial
A single blind randomized clinical trial during the rehabilitation of <6-month-old infants with severe acute malnutrition in Bangladesh. Four weeks after the supplementation period, signs of improved ponderal growth (e.g. rate of weight gain and WAZ scores were significantly higher in infants who had been supplemented with the probiotic (B. infantis EVC001) for 28 days.
Preterm infant fecal microbiota and metabolite profiles are modulated in a probiotic specific manner
In this single-center observational cohort study demonstrates that supplementing an HMO-catabolizing Bifidobacterium probiotic (B. infantis EVC001) results in increased microbial metabolism of milk oligosaccharides and reduced intestinal inflammation relative to a non-catabolizing Lactobacillus probiotic in human milk-fed preterm infants
Bifidobacterium infantis EVC001 administration is associated with a significant reduction in incidence of Necrotizing Enterocolitis in very low birth weight infants
A retrospective observational analysis of two cohorts of very low birth weight (VLBW) infants (+/-) B. infantis EVC001) demonstrated that B. infantis EVC001 was associated with a significant reduction in necrotizing enterocolitis (NEC) and NEC-related mortality.
B. infantis EVC001 is well-tolerated and improves Human Milk Oligosaccharide (HMO) utilization in preterm infants in the neonatal intensive care unit
A prospective, open-label study was used to evaluate the tolerability and HMO-utilization capacity of B. infantis EVC001 and its effects on the fecal microbiota in thirty preterm infants <1,500 g and/or <33 weeks gestation at birth. B. infantis EVC001 was shown to be safe, well-tolerated, and efficient in colonizing the preterm infant gut and able to increase the abundance of bifidobacteria capable of metabolizing HMOs, resulting in significantly improved utilization of human milk.
Bifidobacteria-mediated immune system imprinting early in life
This study identified a correlation between low Bifidobacteria abundance in infant gut microbiome and increased systemic and enteric inflammation. In vitro studies showed fecal metabolites from infants who were colonized with B. infantis EVC001 polarize naïve CD4 T cells away from Th17 (autoimmune) and Th2 (allergic) phenotype towards Th1 (tolerogenic).
Impact of probiotic B. infantis EVC001 feeding in premature infants on the gut microbiome, nosocomially acquired antibiotic resistance, and enteric inflammation
An observational study in premature infants showing changes in microbiome composition, as well as significantly reduced antibiotic resistant gene abundance, enteric inflammation, diaper rash, and antibiotic use in infants fed B. infantis EVC001 compared to infants that were not fed the probiotic.
Symptomatic relief from at-home use of activated Bifidobacterium infantis EVC001 probiotic in infants: results from a consumer survey on the effects on diaper rash, colic symptoms, and sleep
A post-purchase consumer survey reported improvements in diaper rash, gassiness/fussiness, and sleep behavior in infants fed B. infantis EVC001
Comparative Genome Analysis of Bifidobacterium longum subsp. infantis strains reveals variation in human milk oligosaccharide utilization genes among commercial probiotics
Study finds important differences in the genetic makeup of commercial B. infantis strains, specifically on genes related to the metabolization of human milk oligosaccharides. Compared to H5 positive which are fully equipped, H5 negative strains are missing genes related to HMO uptake and attain lower density in vitro and in vivo in a proof-of-concept study.
Colonization by B. infantis EVC001 modulates enteric inflammation in exclusively breastfed infants
Analysis of fecal samples of a subset of infants from a randomized open-label trial to determine the effects of supplementing the probiotic Bifidobacterium longum subsp. infantis for the first 21 days finds 40d old control infants exhibit chronic enteric inflammation, which is significantly different from infants colonized with B. infantis EVC001.
N-glycans from human milk glycoproteins are selectively released by an infant gut symbiont in vivo
Analysis of fecal samples of a subset of infants from a randomized open-label trial to determine the effects of supplementing the probiotic Bifidobacterium longum subsp. infantis for the first 21 days. Study finds a significantly higher abundance of N-glycans released from milk glycoproteins in the infants fed EVC001 group compared with exclusively breastfed controls.
Early-life gut microbiome modulation reduces the abundance of antibiotic-resistant bacteria
Analysis of infants’ fecal samples from a randomized open-label trial to determine the effects of supplementing the probiotic Bifidobacterium longum subsp. infantis for the first 21 days finds an 80% reduction in the carriage of antibiotic resistance genes (ARGs) in infants colonized with B. infantis.
Colonization of breastfed infants byBifidobacterium longum subsp. infantis EVC001 reduces virulence gene abundance
Analysis of infants’ fecal samples from a randomized open-label trial to determine the effects of supplementing the probiotic Bifidobacterium longum subsp. infantis for the first 21 days finds a significant reduction of gut pathogens (identified by virulence factors) in infants colonized with B. infantis compared to those not fed the probiotic.
Reduced colonic mucin degradation in breastfed infants colonized by Bifidobacterium longum subsp. infantis EVC001
Analysis of fecal samples of a subset of infants from a randomized open-label trial to determine the effects of supplementing the probiotic Bifidobacterium longum subsp. infantis for the first 21 days of life find a significant reduction in mucous erosion in infants colonized with B. infantis EVC001 compared to those not fed the probiotic.
Persistence of supplemented Bifidobacterium longum subsp. infantis EVC001 in breastfed infants
Analysis of fecal samples of a subset of infants from a randomized open-label trial to determine the effects of supplementing the probiotic Bifidobacterium longum subsp. infantis for the first 21 days. A study finds a significantly higher abundance of B. infantis (by qPCR) and relative abundance of Bifidobacterium (by 16S rRNA sequencing) in infants fed with B. infantis EVC001 relative to the microbiome exclusively breasted control infants.
Safety and tolerability of Bifidobacterium longum subspecies infantis EVC001 supplementation in healthy term breastfed infants: a phase 1 clinical trial
Open-label clinical trial to determine the effects of supplementing the probiotic Bifidobacterium longum subsp. infantis EVC001 for the first 21 days of life in healthy term breastfed infants compared with matched-control term infants receiving standard care. B. infantis EVC001 was found to be safely consumed and well-tolerated. Stools were fewer and better formed in infants in infants fed EVC001 group compared with exclusively breastfed controls. Adverse events were those expected in healthy infants and not different between groups.